Ong, Jue-Sheng http://orcid.org/0000-0002-6062-710X
Seviiri, Mathias
Dusingize, Jean Claude
Wu, Yeda http://orcid.org/0000-0002-5977-1526
Han, Xikun http://orcid.org/0000-0002-3823-7308
Shi, Jianxin http://orcid.org/0000-0001-8606-4707
Olsen, Catherine M. http://orcid.org/0000-0003-4483-1888
Neale, Rachel E.
Thompson, John F. http://orcid.org/0000-0002-2816-2496
Saw, Robyn P. M.
Shannon, Kerwin F. http://orcid.org/0000-0001-8538-3132
Mann, Graham J. http://orcid.org/0000-0003-1301-405X
Martin, Nicholas G. http://orcid.org/0000-0003-4069-8020
Medland, Sarah E. http://orcid.org/0000-0003-1382-380X
Gordon, Scott D. http://orcid.org/0000-0001-7623-328X
Scolyer, Richard A. http://orcid.org/0000-0002-8991-0013
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Iles, Mark M. http://orcid.org/0000-0002-2603-6509
Landi, Maria Teresa http://orcid.org/0000-0003-4507-329X
Whiteman, David C. http://orcid.org/0000-0003-2563-9559
MacGregor, Stuart http://orcid.org/0000-0001-6731-8142
Law, Matthew H. http://orcid.org/0000-0002-4303-8821
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1073898)
Article History
Received: 28 September 2022
Accepted: 24 August 2023
First Online: 3 October 2023
Competing interests
: R.A.S has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. All other authors declare no conflict of interest.